ROS overproduction for anti-cancer purposes is a subject of active clinical investigation and is especially used in combination therapies with inhibitors of antioxidant pathways (e.g., targeting glutathione or thioredoxin systems) or traditional chemotherapeutics and with radiotherapy (which induce ROS overproduction) to enhance cancer cell killing and achieve synergistic effects. Here, TXN is linked to cancer.